Orally active small molecule inhibitor of pai-1

Abstract

Methods of treating a metabolic disorder comprising orally administering to the patient a small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1) are described. The treatment with the PAI-1 inhibitor changes at least one metabolic measurement of the patient such as fasting glucose, fasting plasma insulin and fasting plasma LDL when compared to the metabolic measurement of the patient in an untreated condition. The metabolic disorder treated by the methods may include obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, hyperlipidemia, metabolic syndrome, and cardiovascular disease, hypercholesterolemia, familial hypercholesterolemia, or elevated LDL.

Dependencies are inferred from the claim text.